中文摘要：

目的探索罗格列酮对糖尿病合并高血压大鼠血压的影响及其可能的机制。方法选择自发性高血压大鼠24只，采用链脲佐菌素腹腔注射的方法建立糖尿病合并高血压模型，造模后，随机分为对照纽12只，治疗纽12只（罗格列酮灌胃），治疗4周，观察血压变化，检测血清N0和一氧化氮合成酶（NOS）含量，用免疫组织化学染色检测血管内皮素受体A（ETRA）和内皮素受体B（ETRB）表达变化。结果与对照组比较，治疗组大鼠血压明显降低（P〈0．05）；血清NO和N0S含量均明显增高[（29．98±4．86）μmol／Lvs（38．68±4．57）μmol／L，P〈0．01；（15．53±1．19）U／ml vs（17．51±1．48）U／ml，P〈0．01]；心肌ETRA水平无明显变化（P〉0．05），而ETRB表达水平显著升高（P〈0．01）。结论罗格列酮能明显降低糖尿病合并高血压大鼠的血压，产生降压现象的机制可能是通过选择性的上调ETRB表达，提高NOS活性，进而增加NO合成，促进血管舒张实现的。

英文摘要：

Objective To study the effect of rosiglitazone on blood pressure in rats with diabetes mellitus（DM） accompanying hypertension. Methods Twenty-four rats with spontaneous hyper- tension were included in this study. A rat DM accompanying hypertension model was established by intraperitoneal injection of streptozotocin. The rats were divided into control group（n= 12） and rosiglitazone treatment group（n= 12）. Four weeks after streptozotocin treatment,the serum nitric oxide（NO） and nitric oxide synthase（NOS） levels were measured. The animals were then sacrificed and their interventricnlar septum was removed. Expressions of vascular endothelial receptor A（ETRA） and vascular endothelial receptor B（ETRB） in interventricular septum tissue were detected with immunohistochemical staining. Results The blood pressure was significantly lower in rosiglitazone treatment group than in control group（P〈0.05）. The serum NO and NOS levels were significantly higher in rosiglitazone treatment group than in control group（P〈0.01）： No significant difference was found in ETRA expression of rosiglitazone treatment group（P〉0.05）. However,the ETRB expression level was significantly higher in rosiglitazone treatment group than in control group（P〈0. 05）. Conclusion Rosiglitazone can significantly reduce the blood pressure in rats with DM accompanying hypertension by selectively up-regulating the ETRB expression and increasing the activity of NOS and the synthesis of NO, thus promoting vasodilation.